Empirical examination of the neutrophil criterion (>1500 μl-1) currently needed to declare CR in AML

Elihu Estey, Francis Giles, Jorge Cortes, Miloslav Beran, Srdan Verstovsek, Guillermo Garcia-Manero, Stefan Faderl, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Currently, NCI guidelines require that the neutrophil count exceed 1500 before complete remission (CR) may be declared in acute myeloid leukemia (AML). We tested the empirical validity of this formulation by comparing event-free survival (EFS) in CR in (a) 305 patients who met the NCI criteria for CR and (b) 36 patients who met all the criteria for CR except that the neutrophil count at what we considered CR was 1000-1499 (lower neutrophil group) at which time they began post-remission therapy. EFS was statistically identical in both groups. We extended these findings to 752 patients, who met the NCI criteria for CR except that some may have had circulating blasts at "CR"; 82 of the 752 were in the lower neutrophil group. These data suggest that the minimum needed to declare CR in AML be changed from 1500 to 1000.

Original languageEnglish (US)
Pages (from-to)475-479
Number of pages5
JournalLeukemia Research
Volume27
Issue number6
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Neutrophils
Disease-Free Survival
Guidelines
Therapeutics

Keywords

  • 1000 neutrophils
  • 1500 neutrophils
  • AML
  • CR
  • NCI criteria

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Empirical examination of the neutrophil criterion (>1500 μl-1) currently needed to declare CR in AML. / Estey, Elihu; Giles, Francis; Cortes, Jorge; Beran, Miloslav; Verstovsek, Srdan; Garcia-Manero, Guillermo; Faderl, Stefan; Kantarjian, Hagop.

In: Leukemia Research, Vol. 27, No. 6, 01.06.2003, p. 475-479.

Research output: Contribution to journalArticle

Estey, E, Giles, F, Cortes, J, Beran, M, Verstovsek, S, Garcia-Manero, G, Faderl, S & Kantarjian, H 2003, 'Empirical examination of the neutrophil criterion (>1500 μl-1) currently needed to declare CR in AML', Leukemia Research, vol. 27, no. 6, pp. 475-479. https://doi.org/10.1016/S0145-2126(03)00031-6
Estey, Elihu ; Giles, Francis ; Cortes, Jorge ; Beran, Miloslav ; Verstovsek, Srdan ; Garcia-Manero, Guillermo ; Faderl, Stefan ; Kantarjian, Hagop. / Empirical examination of the neutrophil criterion (>1500 μl-1) currently needed to declare CR in AML. In: Leukemia Research. 2003 ; Vol. 27, No. 6. pp. 475-479.
@article{e2dd75c110c343aa9c2b1de8b4e8a105,
title = "Empirical examination of the neutrophil criterion (>1500 μl-1) currently needed to declare CR in AML",
abstract = "Currently, NCI guidelines require that the neutrophil count exceed 1500 before complete remission (CR) may be declared in acute myeloid leukemia (AML). We tested the empirical validity of this formulation by comparing event-free survival (EFS) in CR in (a) 305 patients who met the NCI criteria for CR and (b) 36 patients who met all the criteria for CR except that the neutrophil count at what we considered CR was 1000-1499 (lower neutrophil group) at which time they began post-remission therapy. EFS was statistically identical in both groups. We extended these findings to 752 patients, who met the NCI criteria for CR except that some may have had circulating blasts at {"}CR{"}; 82 of the 752 were in the lower neutrophil group. These data suggest that the minimum needed to declare CR in AML be changed from 1500 to 1000.",
keywords = "1000 neutrophils, 1500 neutrophils, AML, CR, NCI criteria",
author = "Elihu Estey and Francis Giles and Jorge Cortes and Miloslav Beran and Srdan Verstovsek and Guillermo Garcia-Manero and Stefan Faderl and Hagop Kantarjian",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0145-2126(03)00031-6",
language = "English (US)",
volume = "27",
pages = "475--479",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Empirical examination of the neutrophil criterion (>1500 μl-1) currently needed to declare CR in AML

AU - Estey, Elihu

AU - Giles, Francis

AU - Cortes, Jorge

AU - Beran, Miloslav

AU - Verstovsek, Srdan

AU - Garcia-Manero, Guillermo

AU - Faderl, Stefan

AU - Kantarjian, Hagop

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Currently, NCI guidelines require that the neutrophil count exceed 1500 before complete remission (CR) may be declared in acute myeloid leukemia (AML). We tested the empirical validity of this formulation by comparing event-free survival (EFS) in CR in (a) 305 patients who met the NCI criteria for CR and (b) 36 patients who met all the criteria for CR except that the neutrophil count at what we considered CR was 1000-1499 (lower neutrophil group) at which time they began post-remission therapy. EFS was statistically identical in both groups. We extended these findings to 752 patients, who met the NCI criteria for CR except that some may have had circulating blasts at "CR"; 82 of the 752 were in the lower neutrophil group. These data suggest that the minimum needed to declare CR in AML be changed from 1500 to 1000.

AB - Currently, NCI guidelines require that the neutrophil count exceed 1500 before complete remission (CR) may be declared in acute myeloid leukemia (AML). We tested the empirical validity of this formulation by comparing event-free survival (EFS) in CR in (a) 305 patients who met the NCI criteria for CR and (b) 36 patients who met all the criteria for CR except that the neutrophil count at what we considered CR was 1000-1499 (lower neutrophil group) at which time they began post-remission therapy. EFS was statistically identical in both groups. We extended these findings to 752 patients, who met the NCI criteria for CR except that some may have had circulating blasts at "CR"; 82 of the 752 were in the lower neutrophil group. These data suggest that the minimum needed to declare CR in AML be changed from 1500 to 1000.

KW - 1000 neutrophils

KW - 1500 neutrophils

KW - AML

KW - CR

KW - NCI criteria

UR - http://www.scopus.com/inward/record.url?scp=0037409084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037409084&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(03)00031-6

DO - 10.1016/S0145-2126(03)00031-6

M3 - Article

C2 - 12648505

AN - SCOPUS:0037409084

VL - 27

SP - 475

EP - 479

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 6

ER -